Trial · NCT05350202
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | Empagliflozin-treated Patients | 17 | 3,309 | |
| serious | Cardiac failure | Cardiac disorders | Empagliflozin-treated Patients | 14 | 3,309 | |
| serious | Cardiac arrest | Cardiac disorders | Empagliflozin-treated Patients | 3 | 3,309 | |
| serious | Cardiogenic shock | Cardiac disorders | Empagliflozin-treated Patients | 3 | 3,309 | |
| serious | Sudden cardiac death | General disorders | Empagliflozin-treated Patients | 3 | 3,309 | |
| serious | Acute kidney injury | Renal and urinary disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Acute myocardial infarction | Cardiac disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Atrial fibrillation | Cardiac disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Cardio-respiratory arrest | Cardiac disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Cerebrovascular accident | Nervous system disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Hospitalisation | Surgical and medical procedures | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Myocardial infarction | Cardiac disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Sudden death | General disorders | Empagliflozin-treated Patients | 2 | 3,309 | |
| serious | Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | Empagliflozin-treated Patients | 1 | 3,309 | |
| serious | Arrhythmia | Cardiac disorders | Empagliflozin-treated Patients | 1 | 3,309 | |
| serious | Blood pressure increased | Investigations | Empagliflozin-treated Patients | 1 | 3,309 | |
| serious | Cardiac failure chronic | Cardiac disorders | Empagliflozin-treated Patients | 1 | 3,309 | |
| serious | Cardiopulmonary failure | Cardiac disorders | Empagliflozin-treated Patients | 1 | 3,309 | |
| serious | Cardiovascular disorder | Cardiac disorders | Empagliflozin-treated Patients | 1 | 3,309 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Empagliflozin-treated Patients | 1 | 3,309 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05350202/events